Literature DB >> 23323160

Interpretation of changes in circulating tumor cell counts.

Frank Aw Coumans1, Sjoerd T Ligthart, Leon Wmm Terstappen.   

Abstract

The presence of circulating tumor cells (CTCs) in the blood of cancer patients may guide the use of therapy. We investigated how to evaluate a reduction in the number of CTCs after administration of therapy. CTCs were enumerated with the CellSearch system in 111 metastatic breast and 185 metastatic prostate cancer patients before start of a new line of chemotherapy and after initiation of therapy. Different means to express changes in CTC counts were evaluated with respect to overall survival (OS). A static CTC cutoff is the best method to determine whether a therapy is effective. This is exemplified by the highest Cox hazard ratio of 2.1 for OS; three methods to express relative differences performed worse. A lookup table is provided from which the significance of a change in CTCs can be derived. The aim of therapy should be the elimination of all CTCs. A period of 10 to 12 weeks of therapy is needed to reach the treatment effect on CTCs.

Entities:  

Year:  2012        PMID: 23323160      PMCID: PMC3542841          DOI: 10.1593/tlo.12247

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  20 in total

1.  Statistical considerations for enumeration of circulating tumor cells.

Authors:  Arjan G J Tibbe; M Craig Miller; Leon W M M Terstappen
Journal:  Cytometry A       Date:  2007-03       Impact factor: 4.355

2.  Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.

Authors:  G Thomas Budd; Massimo Cristofanilli; Mathew J Ellis; Allison Stopeck; Ernest Borden; M Craig Miller; Jeri Matera; Madeline Repollet; Gerald V Doyle; Leon W M M Terstappen; Daniel F Hayes
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

3.  Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

Authors:  Sabine Riethdorf; Herbert Fritsche; Volkmar Müller; Thomas Rau; Christian Schindlbeck; Brigitte Rack; Wolfgang Janni; Cornelia Coith; Katrin Beck; Fritz Jänicke; Summer Jackson; Terrie Gornet; Massimo Cristofanilli; Klaus Pantel
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

4.  Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.

Authors:  T J N Hiltermann; M M Pore; A van den Berg; W Timens; H M Boezen; J J W Liesker; J H Schouwink; W J A Wijnands; G S M A Kerner; F A E Kruyt; H Tissing; A G J Tibbe; L W M M Terstappen; H J M Groen
Journal:  Ann Oncol       Date:  2012-06-11       Impact factor: 32.976

5.  Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Authors:  David R Shaffer; Margaret A Leversha; Daniel C Danila; Oscar Lin; Rita Gonzalez-Espinoza; Bin Gu; Aseem Anand; Katherine Smith; Peter Maslak; Gerald V Doyle; Leon W M M Terstappen; Hans Lilja; Glenn Heller; Martin Fleisher; Howard I Scher
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

6.  Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.

Authors:  Daniel F Hayes; Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; M Craig Miller; Jeri Matera; W Jeffrey Allard; Gerald V Doyle; Leon W W M Terstappen
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

7.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

8.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Authors:  Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol
Journal:  J Clin Oncol       Date:  2008-07-01       Impact factor: 44.544

9.  Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan.

Authors:  Hiroshi Yagata; Seigo Nakamura; Masakazu Toi; Hiroko Bando; Shinji Ohno; Akemi Kataoka
Journal:  Int J Clin Oncol       Date:  2008-06-14       Impact factor: 3.402

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  19 in total

Review 1.  Challenges in circulating tumor cell detection by the CellSearch system.

Authors:  Kiki C Andree; Guus van Dalum; Leon W M M Terstappen
Journal:  Mol Oncol       Date:  2015-12-25       Impact factor: 6.603

2.  Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.

Authors:  M Thalgott; M M Heck; M Eiber; M Souvatzoglou; G Hatzichristodoulou; V Kehl; B J Krause; B Rack; M Retz; J E Gschwend; U Andergassen; R Nawroth
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-24       Impact factor: 4.553

Review 3.  Recent developments in prognostic and predictive testing in uveal melanoma.

Authors:  Matthew G Field; J William Harbour
Journal:  Curr Opin Ophthalmol       Date:  2014-05       Impact factor: 3.761

4.  Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy.

Authors:  Menno Tamminga; Sanne de Wit; Ed Schuuring; Wim Timens; Leon W M M Terstappen; T Jeroen N Hiltermann; Harry J M Groen
Journal:  Transl Lung Cancer Res       Date:  2019-12

5.  Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.

Authors:  Mark Thalgott; Brigitte Rack; Matthias Eiber; Michael Souvatzoglou; Matthias M Heck; Caroline Kronester; Ulrich Andergassen; Victoria Kehl; Bernd J Krause; Jurgen E Gschwend; Margitta Retz; Roman Nawroth
Journal:  BMC Cancer       Date:  2015-06-09       Impact factor: 4.430

Review 6.  Detection of circulating tumor cells.

Authors:  Sanne de Wit; Guus van Dalum; Leon W M M Terstappen
Journal:  Scientifica (Cairo)       Date:  2014-07-15

7.  Progress in using circulating tumor cell information to improve metastatic breast cancer therapy.

Authors:  Jose Alemar; Eric R Schuur
Journal:  J Oncol       Date:  2013-03-25       Impact factor: 4.375

8.  A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.

Authors:  M Wilbaux; M Tod; J De Bono; D Lorente; J Mateo; G Freyer; B You; E Hénin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-24

9.  Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis.

Authors:  Ana M C Barradas; Leon W M M Terstappen
Journal:  Cancers (Basel)       Date:  2013-12-04       Impact factor: 6.639

Review 10.  The promise of circulating tumor cell analysis in cancer management.

Authors:  Joaquin Mateo; Marco Gerlinger; Daniel Nava Rodrigues; Johann S de Bono
Journal:  Genome Biol       Date:  2014-08-30       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.